NRX PHARMACEUTICALS

NRx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics for the treatment of central nervous system disorders and pulmonary diseases. It addresses life-threatening diseases that often go untreated by researching, developing, and scaling solutions to help people who most desperately need them. The company has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure, and is also developing NRX-100/101 which is the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. In July 2021, the Government of Israel awarded NRx the exclusive worldwide right to develop and market the BriLifeR COVID vaccine developed by the Israel Institute for Biological Research.